AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30958901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 664
Study 30958901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (DMF)
Number of subjects: 664
Study 30958901 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 664
Study 30958901 — intervention group
Group type: COMPARATOR
Intervention: DMF
Number of subjects: 664
Study 29330083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric weight management program delivered in the Healthy Weight Clinics of two federally qualified health centers (FQHC)
Number of subjects: 0
Study 29330083 — intervention group
Group type: COMPARATOR
Intervention: Healthy Weight and Your Child programs delivered in two YMCAs
Number of subjects: 0
Study 24037036 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + aPDT
Number of subjects: 16
Study 24037036 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 16
Study 22968252 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Resistance Training (DRT)
Number of subjects: 137
Study 22968252 — intervention group
Group type: COMPARATOR
Intervention: Diet-Only (DO)
Number of subjects: 137
Study 21360473 — intervention group
Group type: EXPERIMENTAL
Intervention: Advised walking group (AWG)
Number of subjects: 18
Study 21360473 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised walking group (SWG)
Number of subjects: 18
Study 19416932 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination
Number of subjects: 20
Study 19416932 — intervention group
Group type: COMPARATOR
Intervention: Timolol monotherapy
Number of subjects: 20
Study 19416932 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide-timolol combination to Timolol monotherapy
Number of subjects: 20
Study 17803343 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate monotherapy
Number of subjects: 320
Study 17803343 — intervention group
Group type: COMPARATOR
Intervention: Topiramate adjunctive therapy
Number of subjects: 320
Study 17803343 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg/day)
Number of subjects: 320
Study 17803343 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100-200 mg/day)
Number of subjects: 320
Study 17803343 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 320
Study 15163108 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2)
Number of subjects: 5
Study 11256837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 5-fluorouracil (5-FU) (450 mg/m2) and leucovorin (20 mg/m2) for five consecutive days during the first and fifth weeks of radiation therapy (50.4 Gy) (n = 14)
Number of subjects: 28
Study 11256837 — intervention group
Group type: COMPARATOR
Intervention: Oral doxifluridine (700 mg/m2/day) and leucovorin (20 mg/m2) daily during radiation treatment (n = 14)
Number of subjects: 28
Study 11256837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 5-fluorouracil (5-FU)
Number of subjects: 28
Study 11256837 — intervention group
Group type: COMPARATOR
Intervention: Oral doxifluridine
Number of subjects: 28
Study 8447616 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic paracetamol 1000 mg given orally shortly before surgery
Number of subjects: 834
Study 8447616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study 3780584 — intervention group
Group type: COMPARATOR
Intervention: 4 l Golytely (GOL)
Number of subjects: 70
Study 3780584 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Electrolyte Solution (BES)
Number of subjects: 70
Study 3780584 — intervention group
Group type: COMPARATOR
Intervention: GOL
Number of subjects: 70
Study 3780584 — intervention group
Group type: EXPERIMENTAL
Intervention: BES
Number of subjects: 70
Study 29704964 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based Habit Reversal Training (HRT)
Number of subjects: 28
Study 29704964 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 28
Study 26540369 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth system (wireless wristwatch-based monitoring device, weight scale, blood pressure cuff, tablet) used for 6 months
Number of subjects: 41
Study 26540369 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight scale
Number of subjects: 41
Study 24742658 — intervention group
Group type: EXPERIMENTAL
Intervention: elevated cFLC (>57.2 mg/L)
Number of subjects: 352
Study 23404485 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 h training on a portable laparoscopic simulator over a 3 week period
Number of subjects: 20
Study 23404485 — intervention group
Group type: COMPARATOR
Intervention: Control with no training
Number of subjects: 20
Study 20496736 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy with ginger moxibustion at Dazhui (GV 14) and Feishu (BL 13) applied once at specified intervals based on seasonal timing.
Number of subjects: 71
Study 20496736 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy with ginger moxibustion at Dazhui (GV 14) and Feishu (BL 13) applied once every other 10 days during 30 days.
Number of subjects: 71
Study 20496736 — intervention group
Group type: COMPARATOR
Intervention: Quality of life and serum level of IL-13 before and after treatment in all groups.
Number of subjects: 71
Study 18644206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use treatment
Number of subjects: 160
Study 16249929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine (DT) alone
Number of subjects: 502
Study 16249929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine (DT) with 20 microg of pertussis toxoid (DTaP20)
Number of subjects: 502
Study 16249929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine (DT) with 40 microg of pertussis toxoid (DTaP40)
Number of subjects: 502
Study 16249929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine (DT) with 20 microg or 40 microg of pertussis toxoid
Number of subjects: 502
Study 16249929 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria-tetanus vaccine (DT) alone or with pertussis toxoid
Number of subjects: 502
Study 16249929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccine (DT)
Number of subjects: 502
Study 12692474 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 14
Study 12692474 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 14
Study 10906502 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesigyna
Number of subjects: 49
Study 10906502 — intervention group
Group type: COMPARATOR
Intervention: IUD (Nova‐T)
Number of subjects: 49
Study 10906502 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesigyna and IUD
Number of subjects: 49
Study 8665578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 30
Study 8665578 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 30
Study 8665578 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1000 mg
Number of subjects: 30
Study 8665578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8665578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg (2 x 25 mg)
Number of subjects: 30
Study 1449335 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 100 mg three times a day orally (Group E)
Number of subjects: 30
Study 1449335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 30
Study 1449335 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (Group E)
Number of subjects: 30
Study 3713181 — intervention group
Group type: EXPERIMENTAL
Intervention: Bogus pipeline method
Number of subjects: 220
Study 3713181 — intervention group
Group type: COMPARATOR
Intervention: Self-reported group
Number of subjects: 220
Study 29862945 — intervention group
Group type: EXPERIMENTAL
Intervention: MPT64 patch test
Number of subjects: 512
Study 29862945 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch test
Number of subjects: 512
Study 26899529 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation education
Number of subjects: 30
Study 24831401 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurovascular bundle preservation (NBP)
Number of subjects: 40
Study 24831401 — intervention group
Group type: COMPARATOR
Intervention: Conventional thoracotomy (CT)
Number of subjects: 40
Study 24831401 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NBP and CT)
Number of subjects: 40
Study 24041300 — intervention group
Group type: EXPERIMENTAL
Intervention: Truflex articulating stylet
Number of subjects: 154
Study 24041300 — intervention group
Group type: COMPARATOR
Intervention: Portex malleable stylet
Number of subjects: 154
Study 21729789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial angioplasty and stenting
Number of subjects: 451
Study 21729789 — intervention group
Group type: COMPARATOR
Intervention: Aggressive medical management
Number of subjects: 451
Study 19027046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-culture-derived influenza vaccine (CCIV)
Number of subjects: 240
Study 19027046 — intervention group
Group type: COMPARATOR
Intervention: Conventional egg-based vaccine
Number of subjects: 240
Study 16918618 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% p-phenylenediamine (PPD) exposure for 48 hours
Number of subjects: 0
Study 16918618 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent but longer duration and higher concentration exposure to PPD
Number of subjects: 0
Study 16918618 — intervention group
Group type: COMPARATOR
Intervention: Frequent, short duration, and lower concentration exposure to PPD
Number of subjects: 0
Study 15327583 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of Alpha-lipoic acid (ALA)
Number of subjects: 16
Study 15327583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15327583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial ALA (incremental cumulative doses of 0.5, 1.0, 1.5 and 2.0 mg ml(‐1) min(‐1))
Number of subjects: 16
Study 15327583 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ALA after oral supplementation
Number of subjects: 16
Study 10899500 — intervention group
Group type: EXPERIMENTAL
Intervention: Repronex SC
Number of subjects: 0
Study 10899500 — intervention group
Group type: COMPARATOR
Intervention: Repronex IM
Number of subjects: 0
Study 10899500 — intervention group
Group type: COMPARATOR
Intervention: Pergonal IM
Number of subjects: 0
Study 9066509 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresonance therapy (BIT)
Number of subjects: 32
Study 9066509 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) BIT treatment
Number of subjects: 32
Study 8453795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicaprost 2.5 micrograms tds
Number of subjects: 49
Study 8453795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicaprost 5 micrograms tds
Number of subjects: 49
Study 8453795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 3005384 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, 200 mg every 12 hours (n = 9)
Number of subjects: 20
Study 3005384 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate, 20 mg every 12 hours (n = 11)
Number of subjects: 20
Study 3005384 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril with hydrochlorothiazide, 25 mg every 12 hours (days 16 to 28)
Number of subjects: 20
Study 3005384 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril with hydrochlorothiazide, 25 mg every 12 hours (days 16 to 28)
Number of subjects: 20
Study 3005384 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of captopril and enalapril
Number of subjects: 20
Study 29699887 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 22
Study 29699887 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 22
Study 27094522 — intervention group
Group type: EXPERIMENTAL
Intervention: HUK (0.15 Perinatal Assessment Unit/day) for 7 consecutive days
Number of subjects: 30
Study 27094522 — intervention group
Group type: COMPARATOR
Intervention: Routine medication
Number of subjects: 30
Study 25041141 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action Liquid
Number of subjects: 14
Study 25041141 — intervention group
Group type: COMPARATOR
Intervention: CVS brand antacid
Number of subjects: 14
Study 21967854 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1.4 g EPA and DHA)
Number of subjects: 34
Study 20355261 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management (MM) + placebo
Number of subjects: 1383
Study 20355261 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management (MM) + naltrexone
Number of subjects: 1383
Study 20355261 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management (MM) + naltrexone + acamprosate
Number of subjects: 1383
Study 20355261 — intervention group
Group type: COMPARATOR
Intervention: 6 of the 9 treatments
Number of subjects: 1383
Study 18723909 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal betamethasone
Number of subjects: 76
Study 18723909 — intervention group
Group type: COMPARATOR
Intervention: Single course of antenatal betamethasone
Number of subjects: 76
Study 15994623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (ethinyl estradiol 20 microg and levonorgestrel 100 microg)
Number of subjects: 76
Study 15994623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 15994623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive
Number of subjects: 76
Study 12022461 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal pin channel with #330 bur
Number of subjects: 48
Study 12022461 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal pin channel with #329 bur
Number of subjects: 48
Study 12022461 — intervention group
Group type: COMPARATOR
Intervention: No internal retentive features
Number of subjects: 48
Study 10604250 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated plasma
Number of subjects: 49
Study 10604250 — intervention group
Group type: COMPARATOR
Intervention: Fresh-frozen plasma (FFP)
Number of subjects: 49
Study 10604250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SD-treated plasma and FFP
Number of subjects: 49
Study 8566861 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 43
Study 8566861 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole + Ranitidine
Number of subjects: 43
Study 8566861 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 43
Study 2007669 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine, 250 mg twice daily for 6 weeks
Number of subjects: 31
Study 2007669 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin, 500 mg twice daily for 6 weeks
Number of subjects: 31
Study 6126907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (n=30)
Number of subjects: 50
Study 6126907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 50
Study 31088207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance intervention (single session of physical activity)
Number of subjects: 34
Study 31088207 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group (control)
Number of subjects: 34
Study 27871083 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Flex (pressure relief CPAP)
Number of subjects: 24
Study 27871083 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Flex (maximum pressure relief setting)
Number of subjects: 24
Study 27871083 — intervention group
Group type: COMPARATOR
Intervention: Fixed CPAP
Number of subjects: 24
Study 26162251 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% Sodium Hypochlorite with positive pressure irrigation
Number of subjects: 48
Study 26162251 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% Sodium Hypochlorite with negative pressure irrigation
Number of subjects: 48
Study 26162251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study 25195020 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to the GermanIMPACT model
Number of subjects: 300
Study 25195020 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control arm)
Number of subjects: 300
Study 22765965 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin with pegylated liposomal doxorubicin (PLD)
Number of subjects: 663
Study 22765965 — intervention group
Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 663
Study 22765965 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin with PLD
Number of subjects: 663
Study 20029509 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate milk (CHOC)
Number of subjects: 10
Study 20029509 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate replacement beverage (CRB)
Number of subjects: 10
Study 16461202 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR (1.5 mg)
Number of subjects: 1758
Study 16461202 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg)
Number of subjects: 1758
Study 16461202 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 1758
Study 16461202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1758
Study 15290740 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiflexed metatarsophalangeal (MTP) knee position
Number of subjects: 402
Study 15290740 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 402
Study 11403810 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and letrozole
Number of subjects: 0
Study 11403810 — intervention group
Group type: COMPARATOR
Intervention: Testosterone and placebo
Number of subjects: 0
Study 11403810 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study 9215015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) for 10 days
Number of subjects: 170
Study 9215015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 7956751 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-212 (20 mg)
Number of subjects: 38
Study 7956751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2455104 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 200-110 at 3.8 mg b.i.d.
Number of subjects: 20
Study 2455104 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 200-110 at 5.7 mg b.i.d.
Number of subjects: 20
Study 2455104 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 10 mg per day
Number of subjects: 20
Study 30646316 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrandomization consent pragmatic trial
Number of subjects: 2004
Study 30646316 — intervention group
Group type: COMPARATOR
Intervention: Traditional framing in high-stakes scenario
Number of subjects: 2004
Study 30646316 — intervention group
Group type: COMPARATOR
Intervention: New framing in high-stakes scenario
Number of subjects: 2004
Study 30646316 — intervention group
Group type: COMPARATOR
Intervention: Traditional framing in low-stakes scenario
Number of subjects: 2004
Study 30646316 — intervention group
Group type: COMPARATOR
Intervention: New framing in low-stakes scenario
Number of subjects: 2004
Study 30646316 — intervention group
Group type: EXPERIMENTAL
Intervention: Better understanding of postrandomization consent design
Number of subjects: 2004
Study 30646316 — intervention group
Group type: COMPARATOR
Intervention: Personal involvement in control arm
Number of subjects: 2004
Study 28397984 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month multifactorial intervention by primary care nurses including motivational interviews and individualized physical activity prescriptions.
Number of subjects: 368
Study 28397984 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group).
Number of subjects: 368
Study 26187089 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends Helping Friends program (treatment group)
Number of subjects: 101
Study 26187089 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 23993298 — intervention group
Group type: EXPERIMENTAL
Intervention: VesCell therapy
Number of subjects: 20
Study 23993298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 21166564 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel LC
Number of subjects: 40
Study 21166564 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy LC
Number of subjects: 40
Study 18511864 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Platelet Volume (MPV)
Number of subjects: 134
Study 18511864 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Size Deviation Width (PDW)
Number of subjects: 134
Study 18511864 — intervention group
Group type: COMPARATOR
Intervention: Platelet-to-Large-Cell Ratio (P-LCR)
Number of subjects: 134
Study 14963801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation allocation method
Number of subjects: 100
Study 11642629 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent conjugate pneumococcal vaccine (conjugated to CRM197)
Number of subjects: 264
Study 11642629 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (conjugate meningococcus C vaccine, conjugated to CRM197)
Number of subjects: 264
Study 9767199 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg max dose)
Number of subjects: 34
Study 9767199 — intervention group
Group type: COMPARATOR
Intervention: Methadone (60 mg equivalent, free dosing schedule)
Number of subjects: 34
Study 7982295 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 20
Study 7982295 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 20
Study 7982295 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 20
Study 2606882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine treatment
Number of subjects: 20
Study 2606882 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 1116357 — intervention group
Group type: EXPERIMENTAL
Intervention: Headphones with stereophonic music
Number of subjects: 3